000			02029 a2200565 4500
005			20250516021830.0
264		0	_c20111003
008			201110s 0 0 eng d
022			_a1365-2796
024	7		_a10.1111/j.1365-2796.2011.02354.x _2doi
040			_aNLM _beng _cNLM
100	1		_aChristersson, C
245	0	0	_aTreatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction. _h[electronic resource]
260			_bJournal of internal medicine _cSep 2011
300			_a215-23 p. _bdigital
500			_aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdministration, Oral
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntithrombins _xadministration & dosage
650	0	4	_aAspirin _xadministration & dosage
650	0	4	_aAzetidines _xadministration & dosage
650	0	4	_aBenzylamines _xadministration & dosage
650	0	4	_aBiomarkers _xblood
650	0	4	_aBlood Platelets _xdrug effects
650	0	4	_aC-Reactive Protein _xmetabolism
650	0	4	_aComorbidity
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Administration Schedule
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInflammation _xblood
650	0	4	_aInterleukin-10 _xblood
650	0	4	_aInterleukin-18 _xblood
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMyocardial Infarction _xblood
650	0	4	_aP-Selectin _xblood
650	0	4	_aPlatelet Activation _xdrug effects
650	0	4	_aRisk Factors
650	0	4	_aThromboplastin _xmetabolism
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
700	1		_aOldgren, J
700	1		_aWallentin, L
700	1		_aSiegbahn, A
773	0		_tJournal of internal medicine _gvol. 270 _gno. 3 _gp. 215-23
856	4	0	_uhttps://doi.org/10.1111/j.1365-2796.2011.02354.x _zAvailable from publisher's website
999			_c20536314 _d20536314